 PTEN and p27 loss of function mutations are associated with a good prognosis, particularly in obese women. The Her2 / neu oncogene, which indicates a poor prognosis, is expressed in 20 % of endometrioid and serous carcinomas. CTNNB1 (beta-catenin; a transcription gene) mutations are found in 14 – 44 % of endometrial cancers and may indicate a good prognosis, but the data is unclear. Beta-catenin mutations are commonly found in endometrial cancers with squamous cells. FGFR2 mutations are found in approximately 10 % of endometrial cancers, and their prognostic significance is unclear. SPOP is another tumor suppressor gene found to be mutated in some cases of endometrial cancer: 9 % of clear cell endometrial carcinomas and 8 % of serous endometrial carcinomas have mutations in this gene.
